Business Standard

Moderna's Covid vaccine 94.5% effective, edges over Pfizer on storage

Its vaccine's temperature requirements give it an edge over Pfizer's for distribution in India

Moderna
Premium

According to international agencies, the US could have two vaccines authorised for emergency use in December with as many as 60 million doses of the vaccine available this year

Sohini DasReuters Mumbai
Moderna’s investigational vaccine candidate has proven to be 94.5 per cent effective in preventing Covid-19 infection based on the interim data from a large-scale late stage trial, the company said on Monday.

This makes Moderna the second US firm to report late-stage efficacy data from vaccine trials together with Pfizer. Last week, Pfizer and BioNTech vaccine candidates were found to be over 90 per cent effective in interim analysis. Moderna’s interim analysis was based on 95 infections among trial participants who received either a placebo or the vaccine. Only five infections occurred in those who received the vaccine, which is administered

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 16 2020 | 7:52 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com